Nellie Goodin, APRN
Acute Care · Tacoma, WANPI 1336724376
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,334 and has fallen 73.8% since, to $350 in 2025. Among acute care clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$701
- AstraZeneca$482
- Edwards Lifesciences$303
- Amgen$244
- Pfizer$238
- Merck$188
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,257100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 41 | $701 |
| AstraZeneca | 17 | $482 |
| Edwards Lifesciences | 8 | $303 |
| Amgen | 16 | $244 |
| Pfizer | 23 | $238 |
| Merck | 11 | $188 |
| Novo Nordisk | 11 | $180 |
| Boston Scientific | 8 | $160 |
| Johnson & Johnson | 8 | $129 |
| Bayer | 5 | $78 |
| Abiomed | 4 | $72 |
| Boehringer Ingelheim | 4 | $66 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $63 |
| Atricure, Inc. | 3 | $56 |
| Lexicon Pharmaceuticals, Inc. | 3 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $50 |
| Baxter Healthcare | 2 | $49 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Scpharmaceuticals Inc. | 2 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Medtronic | 1 | $14 |
| Cvrx, Inc. | 1 | $12 |
| Surmodics, Inc. | 1 | $9 |
How this compares
$3,257 in reported general payments places this provider in the 90th percentile of 135 acute care providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 117 | $124,732 |
| XareltoRivaroxaban | 48 | $65,570 |
| JardianceEmpagliflozin | 31 | $36,589 |
| BrilintaTicagrelor | 35 | $29,173 |
| EntrestoSacubitril/Valsartan | 22 | $28,524 |
| FarxigaDapagliflozin Propanediol | 11 | $8,238 |
| Ranolazine ErRanolazine | 34 | $3,326 |
| Bisoprolol Fumarate | 76 | $1,425 |
| ClopidogrelClopidogrel Bisulfate | 112 | $1,330 |
| Metoprolol Succinate | 77 | $777 |
| Atorvastatin Calcium | 75 | $647 |
| Carvedilol | 105 | $609 |
| Metoprolol Tartrate | 100 | $449 |
| Rosuvastatin Calcium | 46 | $434 |
| Potassium Chloride | 24 | $428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $238 | $124,732117 claims |
| Johnson & JohnsonXarelto | $129 | $65,57048 claims |
| AstraZenecaBrilinta, Farxiga | $482 | $37,41146 claims |
| Boehringer IngelheimJardiance | $66 | $36,58931 claims |
| NovartisEntresto | $701 | $28,52422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 135 acute care providers in Washington.
Other acute care in Tacoma
- Kristy FrancisTacoma$1K
- Snezana DimovskiTacoma$1K
- Susan EardleyTacoma$1K
- Chito Alfonso ColoradoTacoma$507
- Kimberly TelferTacoma$414
- Tatiana MotschmanTacoma$408
- Grace LavalleyTacoma$297
- Vincent GutierrezTacoma$285
- Natalia IvanovaTacoma$280
- Jennifer HartleySeattle$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.